

Article

New Guaiane-Type Sesquiterpenoids Biscogniauxiaols A–G with Anti-Fungal and Anti-Inflammatory Activities from the Endophytic Fungus *Biscogniauxia Petrensis*

Long Han ^{1,2}, Wen Zheng ^{1,2}, Sheng-Yan Qian ^{1,2}, Ming-Fei Yang ^{1,2}, Yong-Zhong Lu ³, Zhang-Jiang He ^{2,*} and Ji-Chuan Kang ^{1,2,*}

¹ College of Life Sciences, Guizhou University, Guiyang 550025, China

² Engineering and Research Center for Southwest Bio-Pharmaceutical Resources of National Education Ministry of China, Guizhou University, Guiyang 550025, China

³ Guizhou Institute of Technology, School of Food and Pharmaceutical Engineering, Guiyang 550003, China

* Correspondence: zjhe3@gzu.edu.cn (Z.-J.H.); jckang@gzu.edu.cn (J.-C.K.); Tel.: +86-15123943889 (Z.-J.H.); +86-13985588309 (J.-C.K.)

Abstract: Seven undescribed guaiane-type sesquiterpenoids named biscogniauxiaols A–G (1–7) were isolated from the endophytic fungus *Biscogniauxia petrensis* on *Dendrobium orchids*. Their structures were determined by extensive spectroscopic analyses, electronic circular dichroism (EC) and specific rotation (SR) calculations. Compound 1 represented a new family of guaiane-type sesquiterpenoids featuring an unprecedented [5/6/6/7] tetracyclic system. A plausible biosynthetic pathway for compounds 1–7 was proposed. The anti-fungal, anti-inflammatory and multidrug resistance reversal activities of the isolates were evaluated. Compounds 1, 2 and 7 exhibited potent inhibitory activities against *Candida albicans* with MIC values ranging from 1.60 to 6.30 μM , and suppressed nitric oxide (NO) production with IC_{50} ranging from 4.60 to 20.00 μM . Additionally, all compounds (100 $\mu\text{g}/\text{mL}$) enhanced the cytotoxicity of cisplatin in cisplatin-resistant non-small cell lung cancer cells (A549/DDP). This study opened up a new source for obtaining bioactive guaiane-type sesquiterpenoids and compounds 1, 2, and 7 were promising for further optimization as multifunctional inhibitors for anti-fungal (*C. albicans*) and anti-inflammatory purposes.



Citation: Han, L.; Zheng, W.; Qian, S.-Y.; Yang, M.-F.; Lu, Y.-Z.; He, Z.-J.; Kang, J.-C. New Guaiane-Type Sesquiterpenoids Biscogniauxiaols A–G with Anti-Fungal and Anti-Inflammatory Activities from the Endophytic Fungus *Biscogniauxia Petrensis*. *J. Fungi* **2023**, *9*, 393. <https://doi.org/10.3390/jof9040393>

Academic Editor: Gary A. Strobel

Received: 2 March 2023

Revised: 12 March 2023

Accepted: 14 March 2023

Published: 23 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Keywords: endophytic fungus; *Biscogniauxia petrensis*; sesquiterpenoids; anti-fungal activity; anti-inflammatory activity; multidrug resistance reversal activity

1. Introduction

Endophytic fungi are considered a source of new bioactive natural products with the potential to become new drugs [1]. Meanwhile, as the main sources of active sesquiterpenoids with untapped structural diversity and multiple biological activities, endophytic fungi have attracted increasing attention from organic chemists and pharmacologists [2]. Guaiane-type sesquiterpenoids are typical bicyclic sesquiterpenes possessing a [5/7] fused ring skeleton, and [5/7/5], [5/6/5], [5/7/6], [5/5/7] tricyclic chemical scaffolds, [5/5/5/6], [5/5/6/5] tetracyclic systems and [5/5/6/5/5] pentacyclic system were afforded via oxidation and cyclization reactions [3–5]. These compounds usually exhibit potent bioactivities, including anti-fungal, anti-inflammatory, anticancer and multidrug resistance (MDR) reversal activities [6–9]. However, plants are the main source of guaiane-type sesquiterpenoids, such as *Daphne genkwa*, *Pogostemon cablin*, *Xylopiavielana*, *Stellera chamaejasme*, *Artemisia zhongdianensis*, *Curcuma wenyujin* [10–15], and there are few reports in microorganisms, which restricts the development and utilization of such active substances.

In our endeavor to search for new bioactive compounds from the endophytic fungi of medicinal plants, the fungus *Biscogniauxia petrensis* MFLUCC 14-0151 isolated from the *Dendrobium orchids* was investigated [16], leading to the identification of one unusual iridoid

biscogniauxiol A (1), which possesses an unprecedented [5/6/6/7] tetracyclic system and six new [5/7] bicyclic guaiane-type sesquiterpenoids biscogniauxiol B–G (2–7) (Figure 1). Herein, the details of the isolation, a discussion of their structural characterization, a plausible biosynthetic pathway for 1–7 and their bioactivities were reported.




Figure 1. The structures of compounds 1–7.

2. Materials and Methods

2.1. General Experimental Procedures

The optical rotations and CD spectra were measured on Autopol VI in MeOH (Rudolph Research Analytical, Hackettstown, NJ, USA) and Chirascan CD spectrophotometer in MeOH (Applied Photophysics, Leatherhead, UK), respectively. The IR spectra via KBr pellets and UV spectra were recorded on Nicolet iS10 spectrometer (Thermo Fisher Scientific, Madison, WI, USA) and Shimadzu UV2401PC (Shimadzu, Kyoto, Japan), respectively. NMR spectra (500 MHz for ^1H and 125 MHz for ^{13}C) were recorded using Avance III 500 MHz equipment (Bruker, Bremerhaven, Germany). HRFABMS data and HRESIMS data were determined using Fast-atom-bombardment mass spectrometry DFS (Thermo Fisher Scientific, Madison, WI, USA) and Shimadzu LC/MS-IT-TOF mass instrument (Shimadzu, Kyoto, Japan), respectively. Column chromatography was conducted on silica gel (200–300 mesh, Qingdao Puke Abruption Materials Co., Ltd. Qingdao, China) and Sephadex LH-20 (Shanghai Yuanye Bio-Technology Co., Ltd. Shanghai, China). ODS column chromatography was performed using C18 silica gel (Fuji Silysia Chemical Ltd. Kasugai, Japan). TLC was carried out on precoated glass silica gel GF254 plates and compounds were visualized under UV light or via heating silica gel plates sprayed with 5% $\text{H}_2\text{SO}_4/\text{EtOH}$.

2.2. Fungal Material

The fungus *B. petrensis* MFLUCC14-0151 was isolated and identified by our research group [16], and preserved at the China General Microbiological Culture Collection Center (CGMCC 40341), Beijing.

2.3. Fermentation, Extraction and Isolation

Martin modified (MM) medium was inoculated with the aforementioned fungus and incubated in a constant-temperature incubator at 28 °C for 5 d to obtain seed culture. Fermentation was carried out in a conical flask (1 L) containing 200 g of rice and 150 mL of distilled water, and then autoclaving at 120 °C for 30 min. Each flask was inoculated with 10 mL of seed culture and incubated at 28 °C for two months.

The fermented cultures were extracted thrice with 2-fold volume of methanol and the organic solvent was evaporated to a small volume under vacuum, and then suspended in H₂O (10 L) and partitioned successively with 20 L of ethyl acetate and n-Butanol, respectively. The ethyl acetate solution was evaporated under reduced pressure to afford a crude extract (56 g). The extract was separated into 6 fractions (Fr. A1–A6) via silica gel column chromatography using ethyl acetate/methanol (50:1, 25:1, 10:1, 5:1 and 1:1). Fraction A1 (9.825 g) was separated by ODS MPLC eluted with methanol/H₂O (20:80, 40:60, 60:80, and 90:10) to afford 13 sub-fractions A1 (1–13). The fraction A1-1-8 (192 mg) was purified by silica gel column chromatography eluted with dichloromethane/ethyl acetate (1:1) to afford sub-fraction A1-1-8-1 (32 mg). Further purification of fraction A1-1-8-1 via ODS MPLC with H₂O/acetone (90:10) yielded compound **1** (4.8 mg). Fraction A2 (10.73 g) was separated via ODS MPLC eluted with H₂O/ethanol (20:80, *v/v*) to provide 10 sub-fractions A2 (1–10). Fraction A2-1 (189 mg) was purified by silica gel column chromatography eluted with petroleum ether/acetone (2:1) to yield compound **2** (20 mg) and compound **3** (10 mg). Separation of fraction A2-2 (819 mg) via a silica gel column with n-hexane/acetone/chloroform (2:2:1) and Sephadex LH-20 (methanol) yielded compound **4** (25 mg) and compound **5** (22 mg). Fraction A2-3 (1.2 g) was subjected to silica gel column with ethyl acetate/acetone/petroleum ether (1:1:1) and Sephadex LH-20 (methanol) to obtain compound **6** (10 mg) and compound **7** (8 mg).

Biscogniauxiol A (**1**). Colorless solid; $[\alpha]_D^{20} + 36.50$ (*c* 0.20, MeOH); UV (MeOH) λ max (log ϵ) 203 (0.26), 275 (0.01); IR ν max 3438, 2967, 2929, 2872, 1722, 1620, 1488, 1372, 1275, 1224, 1170, 1097, 1075, 955, 855, 771 cm⁻¹; ¹H and ¹³C NMR data, see Table 1; HRFABMS ([M + H]⁺ Calcd for C₁₅H₂₃O₃, 251.1642; found 251.1644).

Table 1. ¹H (500 MHz) and ¹³C (125 MHz) NMR data for compounds 1–3 (δ in ppm, *J* in Hz).

| No. | 1 (In DMSO- <i>d</i> ₆) | | 2 (In CD ₃ OD) | | 3 (In CD ₃ OD) | |
|-------|-------------------------------------|------------------------------|---------------------------|--|---------------------------|------------------|
| | δ_C | δ_H | δ_C | δ_H | δ_C | δ_H |
| 1 | 147.0, CH | 5.93 d (5.7) | 62.75, CH | 2.03 dd (9.8, 7.5) | 52.72, CH | 2.06 m |
| 2 | 130.7, CH | 5.60 d (5.8) | 75.33, CH | 4.23 q (7.0) | 37.04, CH ₂ | 2.09 m |
| 3 | 85.7, C | | 43.10, CH ₂ | 1.66 m | 74.26, CH | 4.07 m |
| 4 | 76.5, C | | 37.15, CH | 2.18 m | 44.75, CH | 1.94 m |
| 5 | 32.3, CH ₂ | 1.61 m 1.43 m | 46.50, CH | 2.27 m | 45.88, CH | 2.02 m |
| 6 | 22.5, CH ₂ | 1.97 m 1.54 m | 28.50, CH ₂ | 1.31 m 1.05 m | 27.58, CH ₂ | 1.57 m 1.19 m |
| 7 | 36.6, CH | 1.87 m | 41.14, CH | 1.66 m | 46.75, CH | 1.69 m |
| 8 | 26.9, CH ₂ | 1.83 m 1.5 m | 30.01, CH ₂ | 1.63 m 1.38 m | 25.44, CH ₂ | 1.91 m 1.34 m |
| 9 | 56.2, CH | 2.44 dd (12.2, 8.0) | 41.85, CH ₂ | 1.82 m | 39.24, CH ₂ | 1.92 m 1.52 m |
| 10 | 80.1, C | | 75.72, C | | 75.37, C | |
| 11 | 23.3, CH ₃ | 1.16 s | 43.47, CH | 1.54 m | 76.59, C | |
| 12 | 25.7, CH ₃ | 1.15 s | 66.29, CH ₂ | 3.46 dd (10.8, 6.7) 3.33 dd (10.8, 7.1) | 68.61, CH ₂ | 3.44 d (7.1) |
| 13 | 72.1, C | | 12.88, CH ₃ | 0.82 d (7.0) | 20.81, CH ₃ | 1.07 s |
| 14 | 71.1, CH ₂ | 3.87 d (8.9) 3.27 d (8.9) | 28.25, CH ₃ | 1.29 s | 28.58, CH ₃ | 1.18 s |
| 15 | 25.0, CH ₃ | 1.08 s | 16.79, CH ₃ | 0.88 d (7.2) | 10.15, CH ₃ | 0.92 d (7.3) |
| 10-OH | -OH | 4.67 s | | | | |

Biscogniauxiol B (**2**). Colorless solid; $[\alpha]_D^{20} - 2.33$ (*c* 0.12, MeOH); UV (MeOH) λ max (log ϵ) 204 (0.46); IR ν max 3403, 2930, 2874, 1640, 1460, 1382, 1162, 1069, 1039, 907, 817 cm⁻¹; ¹H and ¹³C NMR data, see Table 1; (+)-HERMS ([M + Na]⁺ Calcd for C₁₅H₂₈O₃Na, 279.1931; found 279.1927).

Biscogniauxiaol C (3). Colorless solid; $[\alpha]_D^{20}$ -10.78 (c 0.10, MeOH); UV (MeOH) λ max ($\log \epsilon$) 202 (0.35), 218 (0.27); IR ν max 3414, 2930, 1641, 1457, 1383, 1264, 1083, 1049, 940, 887 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 1; HERMS ($[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{15}\text{H}_{28}\text{O}_4\text{Na}$, 295.1880; found 295.1882).

Biscogniauxiaol D (4). Colorless solid; $[\alpha]_D^{20}$ -1.88 (c 0.12, MeOH); UV (MeOH) λ max ($\log \epsilon$) 203 (0.34), 276 (2.02); IR ν max 3432, 2934, 2873, 1633, 1459, 1381, 1046, 939, 907 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 2; HRESIMS ($[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{15}\text{H}_{28}\text{O}_4\text{Na}$, 295.1880; found 295.1870).

Table 2. ^1H (500 MHz) and ^{13}C (125 MHz) NMR data for compounds 4–7 (δ in ppm, J in Hz).

| No. | 4 (In CD_3OD) | | 5 (In CD_3OD) | | 6 (In CDCl_3) | | 7 (In CD_3OD) | |
|-----|--------------------------------|---------------------|--------------------------------|---------------------|-------------------------|----------------------------------|--------------------------------|---------------------|
| | δ_{C} | δ_{H} | δ_{C} | δ_{H} | δ_{C} | δ_{H} | δ_{C} | δ_{H} |
| 1 | 63.06, CH | 2.01 m | 50.34, CH | 2.16 m | 53.38, CH | 2.00 m | 49.84, CH | 2.23 m |
| 2 | 75.33, CH | 4.19 m | 27.52, CH_2 | 1.81 m | 73.90, CH | 4.15 m | 36.99, CH_2 | 2.09 m 1.58 m |
| 3 | 43.19, CH_2 | 1.64 m 1.70 m | 33.78, CH_2 | 1.60 m 1.39 m | 37.14, CH_2 | 2.23 m 1.48 m | 78.75, CH | 3.44 m |
| 4 | 37.28, CH | 2.19 m | 40.09, CH | 2.06 m | 43.77, CH | 1.97 m | 49.52, CH | 1.24 s |
| 5 | 47.14, CH | 2.25 m | 46.13, CH | 2.12 m | 45.87, CH | 1.95 m | 47.20, CH | 1.60 m |
| 6 | 27.45, CH_2 | 0.99 m 1.55 m | 29.82, CH_2 | 1.63 m 1.09 m | 24.64, CH_2 | 1.77 m 1.19 m | 38.52, CH_2 | 1.75 m 1.44 m |
| 7 | 46.40, CH | 1.72 m | 44.58, CH | 1.59 m | 44.92, CH | 1.75 m | 44.54, CH | 1.97 m |
| 8 | 25.53, CH_2 | 1.32 m 1.91 m | 34.90, CH_2 | 2.20 m 1.30 m | 23.69, CH_2 | 1.77 m 1.17 m | 33.34, CH_2 | 1.73 m 1.51 m |
| 9 | 40.49, CH_2 | 1.61 m 1.85 m | 81.10, CH | 3.37 m | 74.62, C | | 46.51, CH_2 | 1.86 m 1.67 m |
| 10 | 75.60, C | | 78.17, C | | 33.86, CH_2 | 1.95 m 1.52 m | 75.95, C | |
| 11 | 76.47, C | | 75.90, C | | 75.82, C | | 157.27, C | |
| 12 | 68.55, CH_2 | 3.43 d (3.7) | 68.77, CH_2 | 3.44 m | 68.54, CH_2 | 3.38 d (10.95) 3.56 d (10.95) | 65.09, CH_2 | 4.01 s |
| 13 | 21.08, CH_3 | 1.06 s | 20.60, CH_3 | 1.06 s | 18.43, CH_3 | 1.04 s | 107.51, CH_2 | 4.95 m 4.82 s |
| 14 | 29.08, CH_3 | 1.29 s | 18.43, CH_3 | 1.14 s | 30.92, CH_3 | 1.19 s | 23.70, CH_3 | 1.25 s |
| 15 | 16.66, CH_3 | 0.90 d (7.0) | 16.04, CH_3 | 0.83 d (7.1) | 10.01, CH_3 | 1.01 d (6.95) | 16.34, CH_3 | 0.96 d (6.4) |

Biscogniauxiaol E (5). Colorless solid; $[\alpha]_D^{20}$ -4.50 (c 0.12, MeOH); UV (MeOH) λ max ($\log \epsilon$) 203 (0.30), 223 (0.12), 275 (0.04); IR ν max 3403, 2956, 1634, 1464, 1380, 1335, 1273, 1192, 1169, 1142, 1087, 1049, 955, 925, 875, 823, 779 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 2; HRESIMS ($[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{15}\text{H}_{28}\text{O}_4\text{Na}$, 295.1880; found 295.1878).

Biscogniauxiaol F (6). Colorless solid; $[\alpha]_D^{20}$ -11.30 (c 0.10, MeOH); UV (MeOH) λ max ($\log \epsilon$) 203 (0.50), 221 (0.25), 280 (0.10), 348 (0.16); IR ν max 3436, 2925, 1636, 1456, 1383, 1318, 1164, 1112, 1060, 1034 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 2; HRESIMS ($[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{16}\text{H}_{28}\text{O}_4\text{Na}$ 307.1880; found 307.1873).

Biscogniauxiaol G (7). Colorless solid; $[\alpha]_D^{20}$ -15.25 (c 0.20, MeOH); UV (MeOH) λ max ($\log \epsilon$) 202 (0.42), 271 (0.02); IR ν max 3417, 2924, 2869, 1638, 1455, 1380, 1066, 1031, 900 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 2; HRESIMS ($[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{15}\text{H}_{28}\text{O}_3\text{Na}$, 277.1774; found 277.1764).

2.4. Quantum Chemical Calculation (ECD)

The systematic random conformational analyses were performed in the GMMX program by using a MMFF94 molecular force field, which afforded a few conformers each, with an energy cutoff of 10 kcal/mol to the global minima. All of the obtained conformers were further optimized using DFT at the B3LYP/6-31G(d) level in CH_3OH by

using Gaussian 09 software [17]. The optimized stable conformers were used for TDDFT [B3LYP/6-311G(2d,p)] computations, with the consideration of the first 20 excitations. The overall ECD curves were all weighted by the Boltzmann distribution. The calculated ECD spectra were subsequently compared with the experimental ones. The ECD spectra were produced by SpecDis 1.70.1 software [18].

2.5. Specific Rotation Calculation (SRC)

Pcmodel program (version 10.075) was used to generate conformers at the MMFF94 force field [18]. Then, the isomers were preoptimized with the molcull program (version 1.9.9) by invoking xTB at GFN2-xTB level [18–21]. The clusters were optimized at B3LYP/def2-TZVP level with ORCA program and ensured the optimized structures have no imaginary frequency. After all the Boltzmann population properties were obtained from the Gibbs free energy calculated at PWPB95/def2-QZVPP with thermal corrections in methanol with the SMD solvation model [22]. Next, the most populated conformations obtained were used for specific optical rotations calculation at the B3LYP/6-311 + g(2d,p) level with the Gaussian 09 program package and integrated according to Boltzmann weighting proportions [17].

2.6. Anti-Fungal Assay

The minimal inhibitory concentration (MIC) values of each compound against *Candida albicans* (336485) (BeNa Culture Collection, Henan, China), were determined using the broth microdilution method [23]. Briefly, the screened compounds were 2-fold serially diluted in cell suspensions in RPMI 1640 medium. Then, 100 μ L aliquots were added to 96-well plates. The plates were incubated at 35 °C for 24 h. The commercial amphotericin B (AMB) and fluconazole (FCZ) were used as the positive controls. Zero visible growth was considered as the endpoint value according to the guidelines (M27-A3) (CLSI 2008) [24]. All experiments were carried out in triplicate.

2.7. Anti-Inflammatory Assay

RAW264.7 cells (BeNa Culture Collection, Henan, China) were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% Fasting Blood Sugar (FBS). To determine the anti-inflammatory activities of compounds 1–7, the cells were pretreated with fresh DMEM medium (100 μ L/well) containing the tested compounds at various final concentrations (0–100 μ g/mL) for 2 h. Then, the lipopolysaccharide (LPS, 1 μ g/mL) was added and cultured for another 24 h. NO production in the supernatant was assessed using Griess reagents [4]. The absorbance at 540 nm was measured on a microplate reader. Indomethacin was used as the positive control. Meanwhile, the viability of RAW264.7 cells were evaluated by MTT assay to exclude the interference of the cytotoxicity of the test compounds. All the tests were repeated three times.

2.8. Cytotoxicity and MDR Reversal Assay

The cisplatin (DDP) sensitive A549 and resistant A549/DDP cells purchased from IMMOCELL (Xiamen, Fujian, China) were cultured in Roswell Park Memorial Institute (RPMI-1640) or DMEM supplemented with 10% FBS. The tested compounds were prepared at 100 μ g/mL DMSO stocks and diluted with fresh RPMI-1640 medium to final concentrations at 50 μ g/mL and 100 μ g/mL. Before determining MDR reversal activity, the viability of A549 and A549/DDP cells were evaluated by MTT assay to exclude the interference of the cytotoxicity of compounds 1–7. A549 and A549/DDP cells were seeded in 96-well plates (5×10^4 cells/well) for 24 h, and then the medium containing the tested compounds was added (100 μ L/well) and cultured for another 24 h. The absorbance at 490 nm was measured. The MDR reversal activities were assayed via combining cisplatin (20 μ g/mL) and the tested compounds. The verapamil was used as a positive control. All experiments were performed in parallel three times.

2.9. Statistical Analysis

All experiments were performed in triplicates and expressed as mean \pm standard deviation (SD). An unpaired *t*-test was performed for data analyses using the GraphPad Prism software (version 5). $p < 0.05$ indicated a significant difference.

3. Results and Discussion

3.1. Structure Identification of Compounds 1–7

Biscogniauxiaol A (**1**) was isolated as a colorless solid with the molecular formula $C_{15}H_{22}O_3$ determined by the HRFABMS (Figures S7 and S8), indicating five degrees of unsaturation. The infrared (IR) (Figures S9 and S10) spectrum of **1** displayed characteristic absorption bands for hydroxy (3438 cm^{-1}) and double bond (1620 cm^{-1}) functionalities. The ^1H nuclear magnetic resonance (NMR) (Figure S1) data (Table 1) showed signals of three singlet methyls at δ_{H} 1.08 (H-15), 1.15 (H-12) and 1.16 (H-11), one D_2O -exchangeable proton at δ_{H} 4.67 (10-OH), and two olefinic protons at δ_{H} 5.60 (1H, d, $J = 5.7\text{ Hz}$, H-2) and δ_{H} 5.93 (1H, d, $J = 5.8\text{ Hz}$, H-1). Followed by the interpretation of the ^{13}C NMR (DEPT) (Figure S2) spectrum (Tables S1–S12), fifteen carbon resonances included three methyls, four methylenes (one ether oxygen at δ_{C} 71.1), four methines (two olefinic carbons at δ_{C} 130.7, 147.0) and four oxy-nonprotonated carbons. The presence of one double bond accounted for one of the five degrees of unsaturation, suggesting that compound **1** required a tetracyclic skeleton (rings A–D).

The planar skeleton of **1** was constructed by interpretation of 2D NMR spectra (Figure 2). In the heteronuclear multiple bond correlation (HMBC) (Figure S5) spectrum, the correlations from the active hydrogen 10-OH to C-1/C-9/C-10/C-11 and from H-2 to C-1/C-3/C-9/C-10 suggested the presence of a five-membered cycloolefin structure (ring A) with a hydroxyl at C-10. The correlations from H_3 -12 to C-2/C-3/C-4/C-5 confirmed that C-4 was adjacent to C-3 and C-5. A spin system from C-5 to C-9 was established based on the ^1H - ^1H COSY (Figures S3 and S4) correlations between H-5/H-6/H-7/H-8/H-9. Meanwhile, the connection between C-3 and C-9 was confirmed by HMBC correlations from H-5 to C-3/C-4/C-6/C-7 and from H-9 to C-3/C-10/C-8/C-4/C-11. The above data showed that C-3 to C-9 constructed a seven-membered ring structure. Further analyses of the HMBC correlations from H_3 -15 to C-7, C-13 and C-14 indicated that C-3 was adjacent to C-7. The HBMC correlations from H_3 -14 to C-7, C-13 and C-15 confirmed that C-3 was connected to C-14. Based on the HMBC correlations from H-14 to C-3, chemical shifts of C-4 (δ_{C} 76.5), C-3 (δ_{C} 85.7), C-13 (δ_{C} 72.1) and C-14 (δ_{C} 71.1) and the molecular formula of **1**, two ether bridges between C-4 and C-13, and C-3 and C-14 were determined. Thus, the planar structure and [5,6,6,7] ring skeleton of **1** were confirmed (Figure 1).

The relative configuration of **1** was established by analysis of the rotating-frame nuclear Overhauser effect spectroscopy (ROESY) (Figure S6) spectrum (Figure 3). The ROESY interactions of H-7/H-9/ H_3 -12/ H_3 -15 and H-9/10-OH indicated that these protons had the same orientation. The absolute configuration of **1** was determined by the time-dependent density-functional theory (TD-DFT) quantum calculation of two possible isomers. As shown in Figure 4, the calculated electronic circular dichroism (ECD) spectrum of $3R,4S,7R,9S,10R,13R$ -**1** matched well with the experimental one, which assigned its absolute configuration. Finally, compound **1** was named Biscogniauxiaol A, which was the first reported example of a [5/7] bicyclic sesquiterpenoid with an unprecedented [5/6/6/7] ring system.




Figure 2. Key ^1H - ^1H COSY and HMBC of compounds 1–7.




Figure 3. Key ROESY correlations of compounds 1–7.

Biscogniauxiaol B (**2**) was obtained as a colorless solid with the molecular formula $\text{C}_{15}\text{H}_{28}\text{O}_3$ determined by the HRESIMS (Figures S11 and S12), and a corresponding two degrees of unsaturation. The ^1H NMR data (Table 1) showed signals of three methyls at δ_{H} 0.82 (3H, d, $J = 7.2$ Hz, H-14), δ_{H} 0.88 (3H, d, $J = 7.0$ Hz, H-15), and δ_{H} 1.29 (3H, s, H-11). The ^{13}C NMR (DEPT) (Figure S13) spectrum (Table 1) displayed 15 carbon resonances, which were recognized as three methyls, five methenes and six methines. The planar skeleton of **2** was constructed by interpretation of 2D NMR spectra (Figure 2). The COSY (Figures S14 and S15) correlations between H-1/H-2/H-3/H-4/H-5 and from H₃-15 to H-4 constructed a five-membered ring structure (A). Furthermore, the COSY correlations between H-5/H-6/H-7/H-8/H-9 and the HMBC (Figure S16) correlations from H-9 to C-10, C-14 and C-1 constructed a seven-membered ring structure (B). The COSY correlations between H-7/H-11/H-12/H-13 suggested the presence of a isobutanol moiety at C-7. Finally, the planar structure of **2** was determined as shown in Figure 1. Its relative configuration was established by careful analyses of the ROESY (Figures S17–S22) spectrum (Figure 3). The ROESY correlations H-1/H-4, H-1/H-7, H-7/H-5, H-1/H₃-14

and H₃-14/H-2 indicated that these protons were cofacial. Its absolute configuration was determined by the time-dependent density-functional theory quantum calculation of two possible isomers. The calculated electronic circular dichroism (ECD) spectrum of 1*S*,2*R*,4*S*,5*S*,7*R*,10*S*-2 fitted well with the experimental one (Figure 4), which determined its absolute configuration.




Figure 4. Experimental and calculated ECD spectrum of compounds 1, 2, 5, and 7.

Biscogniauxiol C (**3**) was purified as a colorless solid with the molecular formula C₁₅H₂₈O₄ determined by the HRESIMS (Figures S29–S31), suggesting two degrees of unsaturation. A detailed comparison of its ¹H (Figure S23) and ¹³C NMR (Figure S24) spectroscopic data (Table 1) with that reported for bicyclic sesquiterpene [25] indicated that **3** was tetrahydroxy derivatives of guaiane-type sesquiterpene. The ¹³C NMR (DEPT) (Figure S24) spectra of **3** displayed fifteen carbons consisting of three methyls, five methylenes of which one was oxygenated at δ_C 68.61, five methines of which one was oxygenated at δ_C 74.26 and two quaternary carbons that were oxygenated at δ_C 75.37 and 76.59. The analyses of COSY (Figures S25 and S26) and HMBC spectra (Figure S27) confirmed that **3** contained a guaiane-type sesquiterpene skeleton. The connection between C-11 and C-7 was confirmed by the HMBC correlations from H-7 to C-11. These data indicated that **3** shared the same planar structure as that of 1*R*,3*S*,4*R*,5*S*,7*R*,10*R*,11*S*-guaiane-3,10,11,12-tetraol [25]. However, comparison of their optical rotations and NMR data suggested that they were not identical but stereoisomeric. The relative configuration of **3** was assigned by the ROESY (Figure S28) spectrum (Figure 3). The ROESY correlations of H₃-15/H₃-14, H₃-14/H-7 and H-7/H₃-13 established that they were cofacial. Meanwhile, correlations between H-4 to H-1/H-3/H-5 indicated that these protons were on the same orientation of the molecule. The absolute configuration of **3** was determined by SR calculation of two possible isomers [26]. The calculated SR value for 1*S*,3*S*,4*S*,5*R*,7*S*,10*S*,11*S*-3 at the B3LYP/TZVP level was nearly consistent with the experimental SR value [α]_D²⁰ -10.78 (*c* 0.10, MeOH) (Figure S32), which assigned the absolute configuration of **3** as 1*S*,3*S*,4*S*,5*R*,7*S*,10*S*, and 11*S*.

Biscogniauxiol D (**4**) was obtained as a colorless solid with the molecular formula C₁₅H₂₈O₃ established by the HRESIMS (Figure S39), implying two degrees of unsaturation.

The ^{13}C NMR (DEPT) (Figures S33 and S34) spectra of **4** (Table 2) revealed the presence of fifteen carbons consisting of three methyls, five methylenes of which one was oxygenated at δ_{C} 68.55, five methines of which one was oxygenated at δ_{C} 75.33 and two quaternary carbons that were oxygenated at δ_{C} 75.60 and δ_{C} 76.47. Its ^1H and ^{13}C NMR spectroscopic data were similar to that of compound **3**, indicating that compound **4** was a tetrahydroxy derivative of guaiane-type sesquiterpenes. The COSY (Figure S35) correlations of H-1 to oxidic H-2 and H-4 to H-3 suggested that the C-2 rather than C-3 was oxidized. In the analyses in combination with HMBC (Figures S36 and S37) and COSY spectrum correlations, the planar structure of compound **4** was elucidated as shown (Figure 1). The relative configuration of **4** was assigned by the ROESY (Figure S38) spectrum (Figure 3). The ROESY correlations H-1/H₃-14, H₃-14/H-2, H-2/H-5/H₃-15, H-5/H-7 and H-7/H₃-13 established that they were cofacial. Its absolute configuration was also determined by SR calculation of two possible isomers. The calculated SR value of 1*R*,2*R*,4*R*,5*R*,7*S*,10*S*-**4** at B3LYP/def2-TZVP level matched well with the experimental SR value $[\alpha]_{\text{D}}^{20} -1.88$ (*c* 0.12, MeOH) (Figures S40–S42). Thus, its absolute configuration was determined as 1*R*,2*R*,4*R*,5*R*,7*S*, and 10*S*.

Biscogniauxiaol E (**5**) was isolated as a colorless solid and had the molecular formula $\text{C}_{15}\text{H}_{28}\text{O}_4$ established by the HRESIMS (Figure S49), indicating 2 degrees of unsaturation. Its ^1H and ^{13}C NMR spectroscopic data were similar to that of compound **3**, suggesting that compound **5** was a tetrahydroxy derivative of guaiane-type sesquiterpenes. The ^{13}C NMR (DEPT) (Figures S43 and S44) spectra of **5** (Table 2) had fifteen carbons consisting of three methyls, five methylenes of which one was oxygenated at δ_{C} 68.77, five methines of which one was oxygenated at δ_{C} 81.10 and two oxygenated carbons at δ_{C} 75.90 and 78.17. The COSY (Figure S45) correlations of H-9 to H-8 and the HMBC (Figures S46 and S47) correlations of H-14 to C-10 and H-13 to C-11 and C-12 confirmed that four hydroxyls were located at C-9, C-10, C-11 and C-12. The relative configuration of **5** was assigned by the ROESY (Figure S48) spectrum (Figure 3). The ROESY correlations H-1/H-9 and H-9/H-7 established that they were cofacial. Meanwhile, the ROESY correlations H₃-14/H₃-15/H-5 indicated that they were cofacial. The absolute configuration of **5** was determined by the time-dependent density-functional theory quantum calculation of two possible isomers. As shown in Figure 4, the calculated electronic circular dichroism (ECD) spectrum of the 1*S*,4*R*,5*S*,7*R*,9*R*,10*R*-**5** matched well with the experimental one, which assigned its absolute configuration.

Biscogniauxiaol **6** (**F**) was isolated as a colorless solid and its molecular formula $\text{C}_{15}\text{H}_{28}\text{O}_4$ was established by the HRESIMS (Figure S60), corresponding to two degrees of unsaturation. The ^{13}C NMR (DEPT) (Figure S55) spectra of **6** (Table 2) had fifteen carbons consisting of three methyls, five methylenes of which one was oxygenated at δ_{C} 68.54, five methines of which one was oxygenated at δ_{C} 73.90 and two quaternary carbons oxygenated at δ_{C} 74.62 and 75.82. Careful analyses of the ^1H NMR (Figures S50–S54) and HSQC (Figure S57) data revealed that **6** had three methyl groups (δ_{H} 1.01, δ_{C} 10.01; δ_{H} 1.04, δ_{C} 18.43; δ_{H} 1.19, δ_{C} 30.92), five methylene groups of which one was oxygenate (δ_{H} 3.38 and δ_{H} 3.56, δ_{C} 68.54), and five methine groups of which one was oxygenate (δ_{H} 4.15, δ_{C} 73.90). The COSY (Figure S56) correlations of H-2 to H-1/H-3 and the HMBC (Figure S58) correlations of H-14 to C-10 and H-13 to C-11 and C-12 confirmed that four hydroxyls were located at C-2, C-9, C-11 and C-12 (Figure 2). The relative configuration of **6** was assigned by the ROESY (Figure S59) spectrum (Figure 3). The ROESY correlations H-7/H-5, H-5/H-1 and H-1/H₃-15 established that they were cofacial. The ROESY correlations H-4/H-2 and H-4/H₃-14 established that they were cofacial. The absolute configuration of **6** was also determined by SR calculation of two possible isomers. The SR value of the 1*S*,2*R*,4*S*,5*S*,7*S*,9*R*,11*R*-**6** agreed with the experimental SR value $[\alpha]_{\text{D}}^{20} -11.30$ (*c* 0.10, MeOH) (Figures S61–S63), which assigned its absolute configuration.

Biscogniauxiol G (**7**) was obtained as a colorless solid with the molecular formula $C_{15}H_{26}O_3$ deduced by the HRESIMS (Figures S70–S75), indicating three degrees of unsaturation. Its 1H (Figure S64) and ^{13}C NMR (Figure S65) spectroscopic data were similar to those of compounds **2** and **3**. The ^{13}C NMR (DEPT) (Figure S65) spectra of **7** (Table 2) had fifteen carbons consisting of two methyls, six methylenes of which one was oxygenated at δ_C 65.09, five methines of which one was oxygenated at δ_C 78.75. The HMBC (Figures S66–S68) correlations H_3-14 to $C-10$ and $H-12$ to $C-11/C-13$ and their chemical shift confirmed that three hydroxyls were located at $C-3$, $C-10$ and $C-12$ (Figure 2). The ^{13}C NMR data and HMBC correlations demonstrated the presence of two sp^2 carbons (δ_C 107.51 and 157.27) at $C-11$ and $C-13$. The relative configuration of **7** was assigned by the ROESY (Figure S69) spectrum (Figure 3). The ROESY correlations of $H-1/H-3$, $H-3/H_3-15$, $H-7/H-5$ and $H-5/H_3-15$ indicated that they were cofacial. The absolute configuration of **7** was determined by the time-dependent density-functional theory quantum calculation of two possible isomers. As shown in Figure 4, the ECD spectrum of the $1S,3R,4R,5R,7S,10S-7$ matched with the experimental one, which allowed the assignment of the absolute configuration of **7** as $1S,3R,4R,5R,7S$, and $10S$.

It was acknowledged that farnesyl diphosphate (FPP), the precursor of guaiane-type sesquiterpenoids, was substituted by various hydroxyls via oxidation reactions to afford oxidized guaiane-type sesquiterpenoids [27]. Therefore, a plausible biosynthetic pathway for **1–7** was proposed (Figure 5).




Figure 5. Plausible biosynthetic pathway of compounds **1–7**.

3.2. Results of Bioactivity Assays

3.2.1. Anti-Fungal Evaluation of Compounds

In consideration of the previously discovered anti-fungal activities for guaiane-type sesquiterpenoids [28], the inhibitory effects of compounds **1–7** against *C. albicans* (336485) were evaluated. As shown in Table 3, all compounds had inhibitory activities against *C. albicans*. Among them, compounds **1**, **2**, and **7** exhibited as potent with MICs of 1.60, 6.25 and 6.30 μM , respectively (Amphotericin B and Fluconazole with MICs of 0.43 and 2.61 μM , respectively).

Table 3. The inhibitory activities of compounds 1–7 against *C.albicans*.

| Compounds | MIC (μM) |
|-----------------------------|-----------------------|
| 1 | 1.60 |
| 2 | 6.25 |
| 3 | 23.53 |
| 4 | 12.50 |
| 5 | 11.76 |
| 6 | 47.06 |
| 7 | 6.30 |
| Amphotericin B ^a | 0.43 |
| Fluconazole ^b | 2.61 |

^a Amphotericin B and ^b Fluconazole: the positive controls.

3.2.2. Anti-Inflammatory Activities of Compounds

The anti-inflammatory is one of the most important biological activities for guaiane-type sesquiterpenoids [29]. The inhibitory effects of compounds 1–7 on the LPS-induced production of NO in the RAW264.7 cell line were evaluated in vitro. The results showed that compounds 1, 2, and 7 suppressed the NO production with IC₅₀ values of 4.60 ± 0.42 , 20.00 ± 1.54 and 18.38 ± 1.12 μM , respectively (indomethacin, IC₅₀ = 22.94 ± 1.42 μM), and none of the compounds exhibited cytotoxicity (Table 4).

3.2.3. Anti-cancer and MDR Reversal Effects of Compounds

According to literature reports, guaiane-type sesquiterpenoids had anticancer and MDR reversal activities [30,31]. Thus, the anti-cancer and reversal activities of compounds 1–7 in the cisplatin sensitive A549 cells and resistant A549/DDP cells were evaluated in vitro, respectively. The data displayed that all compounds showed no cytotoxicity to the cisplatin sensitive A549 cells and resistant A549/DDP cells at concentration of 100 $\mu\text{g}/\text{mL}$ (Figure 6). However, they had weak reversal activities to the cisplatin resistant A549/DDP cells at concentrations of 50 $\mu\text{g}/\text{mL}$ and 100 $\mu\text{g}/\text{mL}$ compared to the control group DDP (Figures 7 and 8).




Figure 6. Inhibition effects of the isolates at concentration of 100 $\mu\text{g}/\text{mL}$ on A549 and A549/DDP. ^{ns} $p > 0.05$ compared to the negative group (DMSO).

Table 4. The inhibitory effects of compounds 1–7 on NO production in LPS-stimulated RAW264.7.

| Compounds | IC ₅₀ (μM) | CC ₅₀ (μM) |
|---------------------------|-----------------------|-----------------------|
| 1 | 4.60 ± 0.42 | >80 |
| 2 | 20.00 ± 1.54 | >100 |
| 3 | 60.20 ± 0.81 | >80 |
| 4 | 62.48 ± 1.23 | >100 |
| 5 | 50.76 ± 0.68 | >100 |
| 6 | 75.50 ± 0.73 | >100 |
| 7 | 18.38 ± 1.12 | >100 |
| Indomethacin ^a | 22.94 ± 1.42 | >100 |

^a Indomethacin: the positive control.




Figure 7. Reversal activities of the isolates at concentration of 50 μg/mL against A549/DDP. DDP: cisplatin; Ver: the positive drug verapamil. *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$ and ^{ns} $p > 0.05$ compared to the control group (DDP), respectively. The following are the same.




Figure 8. Reversal activities of the isolates at concentration of 100 μg/mL against A549/DDP.

4. Conclusions

In summary, seven new bioactive sesquiterpenoids including an unprecedented [5/6/6/7] tetracyclic system iridoid were obtained from the endophytic fungus viz *B. petrensis* on *D. orchids*. Their structures including absolute stereochemistry were determined. A possible biosynthetic pathway for them was proposed, which may promote further chemical synthesis efforts. Compounds **1**, **2**, **7** showed potent inhibitory effects on *C. albicans* with MIC values of 1.60, 6.25 and 6.30 μM , respectively. Meanwhile, they exhibited prominent inhibitory activities against the NO production in the RAW264.7 cells with IC_{50} values of 4.60 ± 0.42 , 20.00 ± 1.54 , 18.38 ± 1.12 μM , respectively. Moreover, all the isolated compounds had weak reversal activities to the cisplatin resistant A549/DDP cells. These data confirmed that the endophytic fungus *B. petrensis* is a new source of bioactive guaiane-type sesquiterpenoids that can replace the plants, and compounds **1**, **2** and **7** (biscogniauxiaols A, B and G) were promising for further optimization as multifunctional inhibitors for anti-fungal (*C. albicans*) and anti-inflammatory purposes.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/jof9040393/s1>, Figure S1. ^1H NMR spectrum of compound **1** in DMSO- d_6 , Figure S2. ^{13}C NMR and DEPT spectrum of compound **1** in DMSO- d_6 , Figure S3. ^1H - ^1H COSY spectrum of compound **1** in DMSO- d_6 , Figure S4. HSQC spectrum of compound **1** in DMSO- d_6 , Figure S5. HMBC spectrum of compound **1** in DMSO- d_6 , Figure S6. ROESY spectrum of compound **1** in DMSO- d_6 , Figure S7. HRFABMS spectrum of compound **1**, Figure S8. UV spectrum of **1** in methanol, Figure S9. IR spectrum of **1** in methanol, Figure S10. CD spectrum of **1** in methanol, Figure S11. Specific Rotation of **1** in methanol, Figure S12. ^1H NMR spectrum of compound **2** in CD3OD, Figure S13. ^{13}C NMR and DEPT spectrum of compound **2** in CD3OD, Figure S14. ^1H - ^1H COSY spectrum of compound **2** in CD3OD, Figure S15. HSQC spectrum of compound **2** in CD3OD, Figure S16. HMBC spectrum of compound **2** in CD3OD, Figure S17. ROESY spectrum of compound **2** in CD3OD, Figure S18. HRESIMS spectrum of compound **2**, Figure S19. UV spectrum of **2** in methanol, Figure S20. IR spectrum of **2** in methanol, Figure S21. CD spectrum of **2** in methanol, Figure S22. Specific Rotation of **2** in methanol, Figure S23. ^1H NMR spectrum of compound **3** in CD3OD, Figure S24. ^{13}C NMR and DEPT spectrum of compound **3** in CD3OD, Figure S25. ^1H - ^1H COSY spectrum of compound **3** in CD3OD, Figure S26. HSQC spectrum of compound **3** in CD3OD, Figure S27. HMBC spectrum of compound **3** in CD3OD, Figure S28. ROESY spectrum of compound **3** in CD3OD, Figure S29. HRESIMS spectrum of compound **3**, Figure S30. UV spectrum of **3** in methanol, Figure S31. IR spectrum of **3** in methanol, Figure S32. Specific Rotation of **3** in methanol, Figure S33. ^1H NMR spectrum of compound **4** in CD3OD, Figure S34. ^{13}C NMR and DEPT spectrum of compound **4** in CD3OD, Figure S35. ^1H - ^1H COSY spectrum of compound **4** in CD3OD, Figure S36. HSQC spectrum of compound **4** in CD3OD, Figure S37. HMBC spectrum of compound **4** in CD3OD, Figure S38. ROESY spectrum of compound **4** in CD3OD, Figure S39. HRESIMS spectrum of compound **4**, Figure S40. UV spectrum of **4** in methanol, Figure S41. IR spectrum of **4** in methanol, Figure S42. Specific Rotation of **4** in methanol, Figure S43. ^1H NMR spectrum of compound **5** in CD3OD, Figure S44. ^{13}C NMR and DEPT spectrum of compound **5** in CD3OD, Figure S45. ^1H - ^1H COSY spectrum of compound **5** in CD3OD, Figure S46. HSQC spectrum of compound **5** in CD3OD, Figure S47. HMBC spectrum of compound **5** in CD3OD, Figure S48. ROESY spectrum of compound **5** in CD3OD, Figure S49. HRESIMS spectrum of compound **5**, Figure S50. UV spectrum of **5** in methanol, Figure S51. IR spectrum of **5** in methanol, Figure S52. CD spectrum of **5** in methanol, Figure S53. Specific Rotation of **5** in methanol, Figure S54. ^1H NMR spectrum of compound **6** in CDCl₃, Figure S55. ^{13}C NMR and DEPT spectrum of compound **6** in CDCl₃, Figure S56. ^1H - ^1H COSY spectrum of compound **6** in CDCl₃, Figure S57. HSQC spectrum of compound **6** in CDCl₃, Figure S58. HMBC spectrum of compound **6** in CDCl₃, Figure S59. ROESY spectrum of compound **6** in CDCl₃, Figure S60. HRESIMS spectrum of compound **6**, Figure S61. UV spectrum of **6** in methanol, Figure S62. IR spectrum of **6** in methanol, Figure S63. Specific Rotation of **6** in methanol, Figure S64. ^1H NMR spectrum of compound **7** in CD3OD, Figure S65. ^{13}C NMR and DEPT spectrum of compound **7** in CD3OD, Figure S66. ^1H - ^1H COSY spectrum of compound **7** in CD3OD, Figure S67. HSQC spectrum of compound **7** in CD3OD, Figure S68. HMBC spectrum of compound **7** in CD3OD, Figure S69. ROESY spectrum of compound **7** in CD3OD, Figure S70. HRESIMS spectrum of compound **7**, Figure S71. UV spectrum of **7** in methanol, Figure S72. IR spectrum of **7** in methanol, Figure S73. a CD

spectrum of **7** in methanol, Figure S73. b Specific Rotation of **7** in methanol, Figure S74. Optimized geometries of predominant conformers for compound **1a** at the B3LYP/6-31G(d) level, Figure S75. Optimized geometries of predominant conformers for compound 3R,4S,7R,9S,10R,13R-1 (**1b**) at the B3LYP/6-31G(d) level, Table S1. Boltzmann distribution of conformers **1a_1–1a_3**, Table S2. Cartesian coordinates of conformers **1a_1–1a_2**, Table S3. Cartesian coordinates of conformers **1a_3**, Table S4. Boltzmann distribution of conformers **1b_1–1b_3**, Table S5. Cartesian coordinates of conformers **1b_1–1b_2**, Table S6. Cartesian coordinates of conformers **1b_3**, Table S7. Gibbs free energies^a and equilibrium populations^b of low-energy conformers of compound **2**, Table S8. Cartesian coordinates for the low-energy reoptimized random research conformers of compound **2** at B3LYP-D3(BJ)/6-31G* level of theory in methanol, Table S9. Gibbs free energies^a and equilibrium populations^b of low-energy conformers of compound **5**, Table S10. Cartesian coordinates for the low-energy reoptimized random research conformers of compound **5** at B3LYP-D3(BJ)/6-31G* level of theory in methanol, Table S11. Gibbs free energies^a and equilibrium populations^b of low-energy conformers of compound **7**, Table S12. Cartesian coordinates for the low-energy reoptimized random research conformers of compound **7** at B3LYP-D3(BJ)/6-31G* level of theory in methanol.

Author Contributions: Writing—original draft, L.H.; investigation, W.Z.; data curation, S.-Y.Q., M.-F.Y. and Y.-Z.L.; writing—review and editing, Z.-J.H. and J.-C.K. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Natural Science Foundation of China (No. 32170019; 31670027; 32160667; 31901947), Qian Kehe ZK (2021) 145/the Basic Project of Guizhou Provincial Natural Science Foundation, Guizhou University Incubation (2020) 19/Guizhou University Incubation Program and Gui Da Ren Ji He Zi (2019) 71/Guizhou University Introduced Talent Research Project.

Institutional Review Board Statement: This article does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data supporting the reported results are provided in Supplementary Materials. The data from manuscript and Supplementary Materials are available for publication, citation, and use.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ye, K.; Ai, H.L.; Liu, J.K. Identification and bioactivities of secondary metabolites derived from endophytic fungi isolated from ethnomedicinal plants of tujia in hubei province: A review. *Nat. Prod. Bioprospect.* **2021**, *11*, 185–205. [PubMed]
2. Amirzakariya, B.Z.; Shakeri, A. Bioactive terpenoids derived from plant endophytic fungi: An updated review (2011–2020). *Phytochemistry* **2022**, *197*, 113130.
3. Zhao, P.; Li, Z.Y.; Qin, S.Y.; Xin, B.S.; Liu, Y.Y.; Lin, B.; Yao, G.D.; Huang, X.X.; Song, S.J. Three unusual sesquiterpenes with distinctive ring skeletons from *Daphne penicillata* uncovered by molecular networking strategies. *J. Org. Chem.* **2021**, *86*, 15298–15306.
4. Ruan, Q.F.; Jiang, S.Q.; Zheng, X.Y.; Tang, Y.Q.; Yang, B.; Yi, T.; Jin, J.; Cui, H.; Zhao, Z.X. Pseudoguaianelactones A–C: Three unusual sesquiterpenoids from *Lindera glauca* with anti-inflammatory activities by inhibiting the LPS-induced expression of iNOS and COX-2. *Chem. Commun.* **2020**, *56*, 1517.
5. Su, L.H.; Geng, C.A.; Li, T.Z.; Ma, Y.B.; Huang, X.Y.; Zhang, X.M.; Chen, J.J. Artatrovirenols A and B: Two cage-like sesquiterpenoids from *Artemisia atrovirens*. *J. Org. Chem.* **2020**, *85*, 13466–13471. [PubMed]
6. Wu, S.H.; He, J.; Li, X.N.; Huang, R.; Song, F.; Chen, Y.W.; Miao, C.P. Guaiane sesquiterpenes and isopimarane diterpenes from an endophytic fungus *Xylaria* sp. *Phytochemistry* **2014**, *105*, 197–204. [PubMed]
7. Li, H.M.; Fan, M.; Xue, Y.; Peng, L.Y.; Wu, X.D.; Liu, D.; Li, R.T.; Zhao, Q.S. Guaiane-type sesquiterpenoids from *Alismatis Rhizoma* and their anti-inflammatory activity. *Chem. Pharm. Bull.* **2017**, *65*, 403–407.
8. Su, L.H.; Ma, Y.B.; Geng, C.A.; Li, T.Z.; Huang, X.Y.; Hu, J.; Zhang, X.; Tang, S.; Shen, C.; Gao, Z.; et al. Artematrovirenins A–P, guaiane-type sesquiterpenoids with cytotoxicities against two hepatoma cell lines from *Artemisia atrovirens*. *Bioorgan. Chem.* **2021**, *114*, 105072.
9. Kim, S.E.; Kim, Y.H.; Kim, Y.C.; Lee, J.J. Torilin, a sesquiterpene from *Torilis japonica*, reverses multidrug-resistance in cancer cells. *Planta. Med.* **1998**, *64*, 333.
10. Wang, J.; Liu, Q.B.; Hou, Z.L.; Shi, S.C.; Ren, H.; Yao, G.D.; Lin, B.; Huang, X.X.; Song, S.J. Discovery of guaiane-type sesquiterpenoids from the roots of *Daphne genkwa* with neuroprotective effects. *Bioorgan. Chem.* **2020**, *95*, 103545.

11. Zhou, Q.M.; Chen, M.H.; Li, X.H.; Peng, C.; Lin, D.S.; Li, X.N.; He, Y.; Xiong, L. Absolute configurations and bioactivities of guaiane-type sesquiterpenoids isolated from *pogostemon cablin*. *J. Nat. Prod.* **2018**, *81*, 1919–1927. [PubMed]
12. Xie, Y.G.; Zhong, X.L.; Xiao, Y.Z.; Zhu, S.L.; Muhammad, I.; Yan, S.; Jin, H.Z.; Zhang, W.D. Vieloplains A-G, seven new guaiane-type sesquiterpenoid dimers from *xylopiavielana*. *Bioorgan. Chem.* **2019**, *88*, 102891.
13. Pan, J.; Su, J.C.; Liu, Y.H.; Deng, B.; Hu, Z.F.; Wu, J.L.; Xia, R.F.; Chen, C.; He, Q.; Chen, J.-C.; et al. Stelleranoids A-M, guaiane-type sesquiterpenoids based on [5,7] bicyclic system from *Stellera chamaejasme* and their cytotoxic activity. *Bioorgan. Chem.* **2021**, *115*, 105251.
14. Dong, W.; Li, T.Z.; Huang, X.Y.; He, X.F.; Geng, C.A.; Zhang, X.M.; Chen, J.J. Artemzhongdianolides A1-A21, antihepatic fibrosis guaiane-type sesquiterpenoid dimers from *Artemisia zhongdianensis*. *Bioorgan. Chem.* **2022**, *128*, 106056.
15. Li, Y.H.; Liu, J.W.; Wu, Y.C.; Li, Y.M.; Guo, F.J. Guaiane-type sesquiterpenes from *Curcuma wenyujin*. *Phytochemistry* **2022**, *198*, 113164. [PubMed]
16. Ma, X.Y.; Nontachaiyapoom, S.; Hyde, K.D.; Jeewon, R.; Doilom, M.K.; Chomnunti, P.; Kang, J.C. Biscogniauxia dendrobii sp. nov. and B. petrensis from Dendrobium orchids and the first report of cytotoxicity (towards A549 and K562) of B. petrensis (MFLUCC 14-0151) in vitro. *S. Afr. J. Bot.* **2020**, *134*, 382–393.
17. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G.A.; et al. *Gaussian 09, Revision C.01*; Gaussian Inc.: Wallingford, CT, USA, 2010.
18. Bannwarth, C.; Ehlert, S.; Grimme, S. GFN2-xTB—An accurate and broadly parametrized self-consistent tight-binding quantum chemical method with multipole electrostatics and density-dependent dispersion contributions. *J. Chem. Theory Comput.* **2019**, *15*, 1652–1671.
19. Lu, T. Molclus Program, Version 1.9.9.5. Available online: <http://www.keinsci.com/research/molclus.html>. (accessed on 3 September 2022).
20. Grimme, S. Exploration of chemical compound, conformer, and reaction space with meta-dynamics simulations based on tight-binding quantum chemical calculations. *J. Chem. Theory Comput.* **2019**, *15*, 2847–2862. [PubMed]
21. Grimme, S.; Bannwarth, C.; Shushkov, P. A robust and accurate tight-binding quantum chemical method for structures, vibrational frequencies, and noncovalent interactions of large molecular systems parametrized for all spd-block elements (Z = 1–86). *J. Chem. Theory Comput.* **2017**, *13*, 1989–2009.
22. Neese, F. The ORCA program system. *Wiley Interdiscip. Rev. Comput. Mol. Sci.* **2012**, *2*, 73–78.
23. Cordisco, E.; Petenatti, E.; Svetaz, L.; Sortino, M. Evaluation of the antifungal photodynamic activity of *Thymophylla pentachaeta* extracts against *Candida albicans* and its virulence factors. *Phytomedicine* **2021**, *90*, 153608. [PubMed]
24. Iraj, A.; Yazdanpanah, S.; Alizadeh, F.; Mirzamohammadi, S.; Ghasemi, Y.; Pakshir, K.; Yang, Y.; Zomorodian, K. Screening the antifungal activities of monoterpenes and their isomers against *Candida* species. *J. Appl. Microbiol.* **2020**, *129*, 1541–1551. [PubMed]
25. Niu, S.; Xie, C.L.; Xia, J.M.; Luo, Z.H.; Shao, Z.Z.; Yang, X.W. New anti-inflammatory guaianes from the Atlantic hydrotherm-derived fungus *Graphostroma* sp. MCCC 3A00421. *Sci. Rep.* **2018**, *8*, 530. [PubMed]
26. Yan, L.H.; Li, P.H.; Li, X.M.; Yang, S.Q.; Liu, K.C.; Wang, B.G.; Li, X. Chevalinulins A and B, proangiogenic alkaloids with a spiro[bicyclo[2.2.2]octane-diketopiperazine] skeleton from deep-sea cold-seep-derived fungus *Aspergillus chevalieri* CS-122. *Org. Lett.* **2022**, *24*, 2684–2688. [PubMed]
27. Ren, Q.; Zhao, W.Y.; Shi, S.C.; Han, F.Y.; Zhang, Y.Y.; Liu, Q.B.; Yao, G.D.; Lin, B.; Huang, X.X.; Song, S.J. Guaiane-type sesquiterpenoids from the roots of *Daphne genkwa* and evaluation of their neuroprotective effects. *J. Nat. Prod.* **2019**, *82*, 1510–1517. [PubMed]
28. Huang, R.; Xie, X.S.; Fang, X.W.; Ma, K.X.; Wu, S.H. Five new guaiane sesquiterpenes from the endophytic fungus *Xylaria* sp. YM 311647 of *Azadirachta indica*. *Chem. Biodivers.* **2015**, *12*, 1281–1286.
29. Liu, T.; Chen, X.Y.; Hu, Y.Z.; Li, M.H.; Wu, Y.T.; Dai, M.H.; Huang, Z.L.; Sun, P.H.; Zheng, J.X.; Ren, Z.; et al. Sesquiterpenoids and triterpenoids with anti-inflammatory effects from *Artemisia vulgaris* L. *Phytochemistry* **2022**, *204*, 113428. [PubMed]
30. Su, L.H.; Zhang, X.T.; Ma, Y.B.; Geng, C.G.; Huang, X.Y.; Hu, J.; Li, T.Z.; Tang, S.; Shen, C.; Gao, Z.; et al. New guaiane-type sesquiterpenoid dimers from *Artemisia atrovirens* and their antihepatoma activity. *Acta. Pharm. Sin. B.* **2021**, *11*, 1648–1666.
31. Zhang, Y.L.; Xu, Q.Q.; Zhou, X.W.; Wu, L.; Wang, X.B.; Yang, M.H.; Luo, J.; Luo, J.G.; Kong, L.Y. Rare dimeric guaianes from *Xylopiavielana* and their multidrug resistance reversal activity. *Phytochemistry* **2019**, *158*, 26–34.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.